Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advertisement
Emily MenendezMuscle Invasive Urothelial Carcinoma | March 23, 2023
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
Read More
Daniel M. Geynisman, MDASCO GU Symposium 2023 | February 23, 2023
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Matthew D. Galsky, MDASCO GU Symposium 2023 | February 17, 2023
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
Zachary BessetteASCO GU Symposium 2023 | February 17, 2023
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Emily MenendezMuscle Invasive Urothelial Carcinoma | January 23, 2023
Researchers examined the impact of care fragmentation on patients receiving neoadjuvant chemotherapy and radical cystectomy.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | December 6, 2022
DLRS-based MLP was clinical useful in distinguishing non-muscle-invasive bladder cancer from muscle-invasive bladder cancer.
Leah LawrenceMuscle Invasive Urothelial Carcinoma | November 28, 2022
MRE11 “has been identified as a candidate predictive biomarker," as higher levels are associated with more ...
Emily MenendezMuscle Invasive Urothelial Carcinoma | October 31, 2022
At a 36-month follow-up, the EFS and OS rates were 74.4% and 83.8% in the ITT group, and 92% of patients underwent RC.
Leah LawrenceMuscle Invasive Urothelial Carcinoma | October 31, 2022
ddMVACx6 was demonstrated to improve progression-free survival compared with GCx4 for muscle-invasive disease.
Leah LawrenceMuscle Invasive Urothelial Carcinoma | October 25, 2022
The data, published in Clinical Genitourinary Cancer, showed a lack of benefit of adjuvant ICIs across multiple subgroups.
Cecilia BrownMuscle Invasive Urothelial Carcinoma | August 15, 2022
A trial utilized atezolizumab, a monoclonal antibody directed at the PD-L1 protein, in patients with MIBC.
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 25, 2022
Clinical trial results showed that immunotherapy drug nivolumab helps reduce cancer recurrence in bladder cancer patients.
GU Oncology Now EditorsMuscle Invasive Urothelial Carcinoma | May 24, 2022
...
Advertisement
Advertisement
Advertisement